Investors

2015 News

Keyword Search
 
2019 | 2018 | 2017 | 2016 | 2015
DateTitle 
Dec 14, 2015CTI BioPharma Receives $10 Million Milestone Payment for TRISENOX®
SEATTLE, Dec. 14, 2015 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA: CTIC) today announced that it has received a $10 million milestone payment from Teva Pharmaceutical Industries Ltd. (Teva) related to the achievement of sales milestones for TRISENOX® (arsenic trioxide). TRISENOX was acquired from CTI BioPharma by Cephalon, Inc. (Cephalon). Cephalon was subsequently acquired by Teva. The milestone was paid pursuant to an acquisition agreement for TRISENOX entered into with Cephalon under... 
Printer Friendly Version
Dec 06, 2015Analysis Of Phase 2 Tosedostat In Combination With Low Dose Cytarabine Shows High Rates Of Response In Elderly Patients With AML
Data presented at 57th American Society of Hematology (ASH 2015) Annual Meeting & Exposition ORLANDO, Fla., Dec. 6, 2015 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced an update on results from an investigator-sponsored Phase 2 trial of tosedostat – the company's investigational oral selective aminopeptidase inhibitor – in elderly patients with either primary (de novo) acute myeloid leukemia (AML) or secondary AML. The data showed a complete r... 
Printer Friendly Version
Dec 05, 2015Analysis of Pivotal Phase 3 Patient Outcomes by Subgroups Shows Treatment with Pacritinib Resulted in Consistent Rates of Reduction in Spleen Volume and Symptom Burden
Results support the effectiveness of pacritinib across intermediate or high-risk myelofibrosis patient subgroups analyzed ORLANDO, Fla., Dec. 5, 2015 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) and Baxalta Incorporated (Baxalta) (NYSE: BXLT) today announced results from a new analysis of the pivotal Phase 3 trial, PERSIST-1, evaluating pacritinib versus best available therapy, excluding treatment with JAK2 inhibitors (BAT), in patients with myelofibrosis. Data... 
Printer Friendly Version
Dec 04, 2015CTI BioPharma Prices Underwritten Public Offering of $55 Million of Convertible Preferred Stock
SEATTLE, Dec. 4, 2015 /PRNewswire/ -- CTI BioPharma Corp. ("CTI") (NASDAQ and MTA: CTIC) today announced the pricing of an underwritten public offering of 55,000 shares of its Series N-2 Preferred Stock, offered at a price to the public of $1,000 per share of Series N-2 Preferred Stock (the "Offering"). Each share of Series N-2 Preferred Stock is convertible at the option of the holder, at any time subject to certain limitations, into shares of our common stock at a conversion price of $1.10 per... 
Printer Friendly Version
Dec 03, 2015CTI BioPharma Announces Proposed Public Offering of Convertible Preferred Stock
SEATTLE, Dec. 3, 2015 /PRNewswire/ -- CTI BioPharma Corp. ("CTI") (NASDAQ and MTA: CTIC) today announced that it intends to offer and sell, subject to market and other conditions, shares of its Series N-2 Preferred Stock in an underwritten public offering (the "Offering"). Each share of Series N-2 Preferred Stock will have a stated value of $1,000 per share and will be convertible at the option of the holder, at any time after issuance and subject to certain limitations, into shares of common st... 
Printer Friendly Version
Nov 24, 2015CTI BioPharma Announces United Kingdom National Cancer Research Institute AML Cooperative Group Advances Tosedostat to Next Stage of "Pick-a-Winner" LI-1 Trial for Older Patients with AML or High-Risk MDS
SEATTLE, Nov. 24, 2015 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma or the Company) (NASDAQ and MTA: CTIC) today announced that the United Kingdom's National Cancer Research Institute (NCRI) Haematological Oncology Clinical Studies Group has chosen to advance tosedostat, the Company's investigative oral aminopeptidase inhibitor, to the second stage of a randomized clinical trial of low-dose cytarabine plus or minus tosedostat in older patients with Acute Myeloid Leukemia (AML) or high risk... 
Printer Friendly Version
Nov 24, 2015CTI BioPharma to Present at 27th Annual Piper Jaffray Healthcare Conference
SEATTLE, Nov. 24, 2015 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA: CTIC) announced today that management will present at the 27th Annual Piper Jaffray Healthcare Conference on Wednesday, December 2, 2015, at 12:00 p.m. EST/6:00 p.m. CET in New York. The presentation will be webcast live and available for replay from the Investors section of CTI BioPharma's website at www.ctibiopharma.com. About CTI BioPharma CTI BioPharma Corp. (NASDAQ and MTA: CTIC) is a biopharmaceutical c... 
Printer Friendly Version
Nov 23, 2015CTI BioPharma Initiates Rolling Submission of U.S. New Drug Application for Pacritinib for the Treatment of Patients with Myelofibrosis
-- Completion of NDA Submission Expected Before the End of 2015 -- SEATTLE, Nov. 23, 2015 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) announced the initiation of its rolling new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1 and CSF1R. As part of the application, CTI BioPharma and its partner, Baxalta Incorporated (Baxalta), are seeking accele... 
Printer Friendly Version
Nov 23, 2015CTI BioPharma Announces Presentation of Preclinical Data Demonstrating Potential Synergistic Combination of Pacritinib and an EGFR Inhibitor in Targeting Brain Tumor Initiating Cells
-- Combination Therapy Has Potential to Improve Outcomes for Patients with Glioblastoma Multiforme (GBM) - SEATTLE, Nov. 23, 2015 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced findings from an investigator-sponsored preclinical study showing the potential synergistic effect of combining pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1 and CSF1R, with an epidermal growth factor receptor (EGFR) inhibitor i... 
Printer Friendly Version
Nov 06, 2015CTI BioPharma Announces Data Presentations at the 57th American Society of Hematology Annual Meeting
SEATTLE, Nov. 6, 2015 /PRNewswire/ -- CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) today announced that data highlighting two compounds (pacritinib and tosedostat) from the company's investigational pipeline will be presented at the upcoming 57th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 5-8 in Orlando, FL – including three oral presentations. The presentations will include data analyses from the Phase 3 PERSIST-1 trial of pacritinib, an inve... 
Printer Friendly Version
Nov 05, 2015CTI BioPharma Reports Third Quarter 2015 Financial Results
- Conference Call Scheduled for Today at 4:30 p.m. Eastern Time - SEATTLE, Nov. 5, 2015 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA: CTIC) today reported financial results for the third quarter ended September 30, 2015. "We are focused on preparing our NDA submission for pacritinib and are on track to submit our application to the FDA this quarter," said James A. Bianco, M.D., CTI BioPharma's President and CEO. "We also remain committed to completing the second Phase 3 trial of p... 
Printer Friendly Version
Oct 29, 2015CTI BioPharma to Report Third Quarter 2015 Financial Results on November 5, 2015
SEATTLE, Oct. 29, 2015 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA: CTIC) announced today that it plans to report its third quarter 2015 financial results on Thursday, November 5, 2015, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a webcast conference call to discuss the results and provide a general corporate update at 4:30 p.m. EST (1:30 p.m. PST). Access to the event can be obtained as follows: Thursday, Novembe... 
Printer Friendly Version
Oct 27, 2015CTI BioPharma Prices Underwritten Public Offering of $50 Million of Convertible Preferred Stock
SEATTLE, Oct. 27, 2015 /PRNewswire/ -- CTI BioPharma Corp. ("CTI") (NASDAQ and MTA: CTIC) today announced the pricing of an underwritten public offering of 50,000 shares of its Series N-1 Preferred Stock, offered at a price to the public of $1,000 per share of Series N-1 Preferred Stock (the "Offering"). Each share of Series N-1 Preferred Stock is convertible at the option of the holder, at any time, into 800 shares of common stock at a conversion price of $1.25 per share of common stock, for a ... 
Printer Friendly Version
Oct 26, 2015CTI BioPharma Announces Proposed Public Offering of Convertible Preferred Stock
SEATTLE, Oct. 26, 2015 /PRNewswire/ -- CTI BioPharma Corp. ("CTI") (NASDAQ and MTA: CTIC) today announced that it intends to offer and sell, subject to market and other conditions, shares of its Series N-1 Preferred Stock in an underwritten public offering (the "Offering"). Each share of Series N-1 Preferred Stock will have a stated value of $1,000 per share and will be convertible at the option of the holder, at any time after issuance, into shares of common stock prior to the automatic convers... 
Printer Friendly Version
Oct 01, 2015CTI BioPharma And Fred Hutchinson Cancer Research Center Announce International Research Fellowship To Support Innovative Blood-Related Cancer Research
SEATTLE, Oct. 1, 2015 /PRNewswire/ -- Seattle-based CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) and Fred Hutchinson Cancer Research Center (Fred Hutch) today announced the establishment of a new $1.5 million research endowment fund – The CTI BioPharma International Postdoctoral Research Fellowship – intended to foster international collaboration in translational research and support advancements in the fields of hematology and immunobiology.     "Establishing this endowed inter... 
Printer Friendly Version
Sep 24, 2015CTI BioPharma Announces $15.7 Million Registered Direct Offering
SEATTLE, Sept. 24, 2015 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA: CTIC) today announced that it has entered into an agreement with institutional investors to purchase 10 million shares of the Company's common stock in a registered direct offering conducted without an underwriter or placement agent for gross proceeds to the Company of approximately $15.7 million at a purchase price per share of $1.57 (the "Offering"), equal to the consolidated closing bid price on The NASDAQ Global Mar... 
Printer Friendly Version
Sep 24, 2015CTI BioPharma to Present at the Ladenburg Thalmann 2015 Healthcare Conference
SEATTLE, Sept. 24, 2015 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA: CTIC) announced today that management will present at the Ladenburg Thalmann 2015 Healthcare Conference on Tuesday, September 29 at 8:00 a.m. PDT/11:00 a.m. EDT/5:00 p.m. CEST in New York. The presentation will also be webcast live and available for replay after the presentation. The webcast can be accessed at www.ctibiopharma.com. About CTI BioPharma CTI BioPharma Corp. (NASDAQ and MTA: CTIC) is a biopharmac... 
Printer Friendly Version
Sep 23, 2015CTI BioPharma To Submit NDA For Pacritinib In Q4 Based Primarily On Data From Single Pivotal Persist-1 Trial
- Decision Follows Pre-NDA Meeting with the FDA to Request Accelerated Approval for Patients with Myelofibrosis and Low Platelet Counts - - Accelerated Approval to Be Requested Based on Single Trial, Potentially Reducing Time to Market - SEATTLE, Sept. 23, 2015 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced its plan to submit a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) following a productive pre-NDA meeting for p... 
Printer Friendly Version
Aug 06, 2015CTI BioPharma Reports Second Quarter 2015 Financial Results
- Positive Phase 3 Results for Pacritinib Demonstrating Significant Clinical Benefit in Patients with Myelofibrosis Presented at ASCO and EHA - - Conference Call Scheduled for Today at 4:30 p.m. Eastern Time - SEATTLE, Aug. 6, 2015 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA: CTIC) today reported financial results for the second quarter ended June 30, 2015. "The significant interest from the oncology community generated by the Phase 3 PERSIST-1 clinical data, presented at the ... 
Printer Friendly Version
Jul 28, 2015CTI BioPharma to Report Second Quarter 2015 Financial Results on August 6, 2015
SEATTLE, July 28, 2015 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA: CTIC) announced today that it plans to report its second quarter 2015 financial results on Thursday, August 6, 2015, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a webcast conference call to discuss the results and provide a general corporate update at 4:30 p.m. EDT (1:30 p.m. PDT). Access to the event can be obtained as follows: Thursday, August 6... 
Printer Friendly Version
Jul 27, 2015CTI BioPharma Appoints Bruce J. Seeley As Executive Vice President and Chief Commercial Officer
SEATTLE, July 27, 2015 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced the appointment of Bruce J. Seeley as Executive Vice President and Chief Commercial Officer, reporting to James Bianco, M.D., CTI BioPharma's President and Chief Executive Officer. Seeley joins CTI BioPharma effective today and will serve on the executive leadership team, assuming responsibility for CTI BioPharma's commercial organization worldwide – including sales, marketing, comme... 
Printer Friendly Version
Jun 15, 2015Tosedostat In Combination With Low Dose Cytarabine Achieves Primary Endpoint In Phase 2 Study In Elderly Patients With AML
Responders Achieve 45 Percent Complete Remission Rate, Nearly Double the Upper Limit of Expected Results; 55 Percent of Responding Patients Remain in Remission for a Median of 319 Days Data Presented at the 20th Congress of the European Hematology Association, June 11-14, 2015 VIENNA, June 15, 2015 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced findings from an investigator-sponsored Phase 2 trial in patients with either primary (de novo) acute... 
Printer Friendly Version
Jun 12, 2015Pacritinib Phase 3 Study Shows Positive Results In Patient Reported Outcomes Measuring Quality Of Life In Patients With Myelofibrosis
Significant Improvements in Symptom Score were Reported with Pacritinib, Across All Measured Symptoms, Compared to Best Available Therapy VIENNA, June 12, 2015 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) and Baxter International's BioScience business (NYSE: BAX) today announced new patient-reported outcome (PRO) data for pacritinib – an investigational oral multikinase inhibitor with specificity for JAK2 and FLT3 – from the Phase 3 PERSIST-1 study. As recently... 
Printer Friendly Version
Jun 10, 2015CTI BioPharma And Baxter Announce Patient-Reported Outcomes (PROs) From Pacritinib Phase 3 In Patients With Myelofibrosis To Be Presented In Late-Breaking Session At EHA
Pacritinib PROs Abstract (#LB2072) also to be Highlighted in the Official EHA Press Program SEATTLE and DEERFIELD, Ill., June 10, 2015 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) and Baxter International's BioScience business (NYSE:BAX) today announced that Patient Reported Outcomes (PROs) data from the Phase 3 PERSIST-1 trial, evaluating pacritinib in patients with myelofibrosis, will be highlighted in a late-breaking oral presentation at the upcoming 20th Co... 
Printer Friendly Version
Jun 10, 2015CTI BioPharma Amends Loan Agreement
SEATTLE, June 10, 2015 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA: CTIC) today announced that it has amended its existing loan agreement with Hercules Technology Growth Capital, Inc. (Hercules). Pursuant to the amendment, Hercules agreed to provide term loans in an aggregate principal amount of up to $25.0 million under the facility, inclusive of amounts outstanding immediately prior to closing of the amendment.  On June 9, 2015, approximately $6.2 million (less fees and expenses) was f... 
Printer Friendly Version
May 30, 2015Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015
Study demonstrates improvement in key disease measurements and disease-related symptoms with pacritinib treatment compared to best available therapy, regardless of platelet levels at the time of enrollment Treatment resulted in improvements in severe thrombocytopenia and severe anemia, eliminating the need for blood transfusions in a quarter of patients who were transfusion dependent at the time of enrollment CHICAGO, May 30, 2015 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASD... 
Printer Friendly Version
May 06, 2015CTI BioPharma Reports First Quarter 2015 Financial Results
- Late-breaking Abstract for Pacritinib Accepted for Presentation at ASCO - - Conference Call Scheduled for Today at 4:30 p.m. Eastern Time - SEATTLE, May 6, 2015 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA: CTIC) today reported financial results for the first quarter ended March 31, 2015. "After reporting positive top-line results from the PERSIST-1 Phase 3 clinical trial of pacritinib during the quarter, we have subsequently received positive feedback from a number of treat... 
Printer Friendly Version
Apr 23, 2015CTI BioPharma to Report First Quarter 2015 Financial Results on May 6, 2015
SEATTLE, April 23, 2015 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA: CTIC) announced today that it plans to report its first quarter 2015 financial results on Wednesday, May 6, 2015, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a webcast conference call to discuss the results and provide a general corporate update at 4:30 p.m. EDT (1:30 p.m. PDT). Access to the event can be obtained as follows: Wednesday, May 6 1:... 
Printer Friendly Version
Apr 22, 2015CTI BioPharma and Baxter Announce Phase 3 Data of Pacritinib in Patients with Myelofibrosis to be Presented in Late-Breaking Session at ASCO
-- Pacritinib Abstract #LBA7006 also to be Highlighted in the Official ASCO Press Program -- SEATTLE and DEERFIELD, Ill., April 22, 2015 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) and Baxter International Inc. (NYSE:BAX) today announced that data from the randomized Phase 3 PERSIST-1 trial evaluating the investigational agent pacritinib in patients with myelofibrosis will be highlighted in a late-breaking oral presentation at the upcoming American Society of ... 
Printer Friendly Version
Mar 16, 2015CTI BioPharma Announces Publication In Blood Of Phase 2 Results Of Pacritinib In Patients With Myelofibrosis
SEATTLE, March 16, 2015 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that results of a Phase 2 study of pacritinib, in patients with myelofibrosis were published in the journal Blood. Pacritinib is a next-generation oral JAK2/FLT3 multikinase inhibitor currently in Phase 3 development in the PERSIST program. Dr. Rami S. Komrokji, Associate Professor of Oncologic Sciences at the University of South Florida College of Medicine and Clinical Director of ... 
Printer Friendly Version
Mar 12, 2015CTI BioPharma Reports Fourth Quarter And Full Year 2014 Financial Results
- Positive Top-Line Results from PERSIST-1 Phase 3 Study of Pacritinib in Patients with Myelofibrosis - - PIXUVRI Receives Reimbursement in Spain - - Total Revenues for Full Year 2014 Reach $60.1 Million - - Conference Call Scheduled for Today at 4:30 p.m. Eastern Time - SEATTLE, March 12, 2015 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA: CTIC) today reported financial results for the fourth quarter and full year ended December 31, 2014. "In 2014, we successfully accomp... 
Printer Friendly Version
Mar 09, 2015CTI BioPharma And Baxter Announce Positive Top-Line Results From Phase 3 Persist-1 Trial Of Pacritinib For Patients With Myelofibrosis
Trial Meets Primary Endpoint in Intent-to-Treat Population Oral Pacritinib is the First Agent with Clinical Data Supporting its Use in Treating Patients with Myelofibrosis Irrespective of Their Platelet Count, Including Severe and Life-Threatening Thrombocytopenia (low platelets) CTI BioPharma to Host Conference Call Today at 8:00 am EDT SEATTLE and DEERFIELD, Ill., March 9, 2015 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) and Baxter International Inc. (... 
Printer Friendly Version
Mar 06, 2015CTI BioPharma to Host Conference Call and Webcast on March 9
SEATTLE, March 6, 2015 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA: CTIC) announced today that its management plans to host a conference call and webcast on Monday, March 9 at 8:00 a.m. EDT (5:00 a.m. PDT). Access to the event can be obtained as follows: Monday, March 9 5:00 a.m. PDT/8:00 a.m. EDT/1:00 p.m. CET 1-888-471-3843 (domestic) +1 719-325-2376 (international) To access the live audio webcast or the subsequent archived recording, visit CTI BioPharma's website, www.ctibi... 
Printer Friendly Version
Feb 26, 2015CTI BioPharma to Report Fourth Quarter and Full Year 2014 Financial Results on March 12, 2015
SEATTLE, Feb. 26, 2015 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ and MTA: CTIC) announced today that it plans to report its fourth quarter and full year 2014 financial results on Thursday, March 12, 2015, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a webcast conference call to discuss the results and provide a general corporate update at 4:30 p.m. EDT (1:30 p.m. PDT). Access to the event can be obtained as follows: Thur... 
Printer Friendly Version
Feb 03, 2015CTI BioPharma Announces Independent DMC Recommendation to Continue GOG-0212 Phase 3 Study of OPAXIO™ as Maintenance Therapy in Ovarian Cancer, an NRG Oncology/GOG Study
SEATTLE, Feb. 3, 2015 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that the Gynecologic Oncology Group, now part of NRG Oncology, informed CTI BioPharma that an independent Data Monitoring Committee (DMC) recommended continuation of the GOG-0212 Phase 3 clinical study of OPAXIO™ (paclitaxel poliglumex) as maintenance therapy in ovarian cancer with no changes following a second of four planned interim analyses for survival and futility. CTI BioPharma ... 
Printer Friendly Version
Jan 12, 2015CTI BioPharma Appoints Alan K. Burnett, M.D. As Therapeutic Area Lead, Myeloid Diseases
SEATTLE, Jan. 12, 2015 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) announced today the appointment of Alan K. Burnett, M.D., to serve as the strategic leader for myeloid development. Dr. Burnett most recently served as Professor and Head of the Department of Haematology in the Institute of Cancer and Genetics at Cardiff University and is highly regarded internationally for his work in the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndr... 
Printer Friendly Version
Jan 08, 2015CTI BioPharma Announces 2015 Outlook and Recent Drug Portfolio Progress
SEATTLE, Jan. 8, 2015 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced an overview of recent progress for its drug portfolio in addition to several anticipated key objectives for 2015. "We ended a productive 2014 and have entered a promising 2015 stronger and more focused than we have been in recent years," said James A. Bianco, M.D., CTI BioPharma's President and Chief Executive Officer. "In the latter part of 2014, we entered into a global developm... 
Printer Friendly Version